HRMY$36.41
Chart
Performance
Key Stats
AI HRMY Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyHarmony Biosciences Holdings, Inc. exhibits strong fundamental performance, particularly in its profitability and revenue growth, supported by a solid balance sheet. While the company is focused on niche neurological diseases, its innovative product pipeline presents good long-term potential. Technical indicators suggest a cautious short-to-medium term outlook.
Thematic
Harmony Biosciences operates in the specialized market of rare neurological diseases. Its focus on novel treatments for conditions like narcolepsy and Prader-Willi Syndrome places it within growing therapeutic areas, but the niche nature and competition are key considerations.
Fundamental
Harmony Biosciences demonstrates robust financial health with consistent revenue growth, improving profitability, and a strong cash position. Its low debt levels and positive free cash flow are significant strengths.
Technical
The stock has shown positive performance over multiple short-term periods but is trading near its 52-week range. Technical indicators suggest mixed signals, with some leaning towards potential overbought conditions and others indicating a neutral to slightly bullish trend.
| Factor | Score |
|---|---|
| Rare Disease Therapeutics | 75 |
| Neurological Disorders Treatment | 80 |
| Competitive Landscape | 50 |
| Regulatory Environment (Pharma) | 60 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 90 |
| Growth | 92 |
| Balance Sheet Health | 85 |
| Cash Flow | 95 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Consistent EPS Beat
Harmony Biosciences Holdings, Inc. (HRMY) has consistently beaten earnings per share (EPS) estimates for the past several quarters, including significant positive surprises in Q4 2024 (+18.8%) and Q3 2024 (+415.81%). This indicates strong operational execution and effective cost management.
Strong Cash Position
The company maintained a robust cash and cash equivalents balance of $453,001,000 as of Q4 2024. Coupled with positive free cash flow ($218,668,000 in 2024), this provides significant financial flexibility for operations, R&D, and potential strategic initiatives.
Bearish Points (6)
High Quarterly P/E Ratio
Despite annual P/E improvements, the quarterly P/E ratio for Q1 2025 is 41.8 and for Q4 2024 was 39.9. These high multiples, especially for a commercial-stage company, could indicate that the stock is trading at a premium and is susceptible to significant downside if growth expectations are not met.
Margin Compression in Recent Quarters
While the annual net margin for 2024 was 20.4%, the Q2 2024 net margin dropped to 6.7%. This significant decline, even if partially recovered in subsequent quarters, warrants attention to potential operational cost increases or pricing pressures impacting profitability.
Calendar
August 2025
5
Next Earnings Date
H: $1.17
A: $1.04
L: $0.85
H: 208.23M
A: 205.31M
L: 201.51M
Profile
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Seasonals
Price Target
49.55 USD
The 39 analysts offering 1 year price forecasts for HRMY have a max estimate of 70.00 and a min estimate of 31.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Primary competitor in the narcolepsy market with established treatments (Xyrem, Xywav), directly competing with Harmony's Wakix.
Weight: 95
Direct competitor with its newly approved once-nightly narcolepsy treatment, Lumryz, posing a significant market challenge to existing therapies.
Weight: 90
Owns Sunosi, a wake-promoting agent for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, directly competing with HRMY's focus.
Weight: 85
Marketed Hetlioz for Non-24-hour sleep-wake disorder and other CNS disorders, sharing a focus on sleep-related neurological conditions.